Single Center Experience on Management of CAR-T Related Thrombocytopenia

Musso M, Tona G, Scalone R, Crescimanno A, Porretto F, Lanza M, Bonanno V, Zammit V, Abbene I, Polizzi V and Iannitto E

Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, La Maddalena, Italy

^*Correspondance to: Maurizio Musso 

 PDF  Full Text Research Article | Open Access

Abstract:

Chimeric Antigen Receptor (CAR) T cells therapy is the standard of care for refractory/recurring Non-Hodgkin B Cell Lymphoma (R/R NHL). Nowadays increasing experience on CAR-T therapy shows that early-onset toxicity (cytokine releasing syndrome and neurotoxicity) is manageable, shifting the attention to late-onset toxicities like cytopenia and infections. Grade ≥ 3 thrombocytopenia occurs in almost one third of patients and still represents an unmet clinical need. Thrombopoietin mimetic (TPOm) Romiplostim, thanks to the results in Aplastic Anemia (AA) and immune thrombocytopenia, is off-label-used in this setting. Our experience on 7 patients with grade ≥ 3 thrombocytopenia, over a cohort of 21 patients who undergone CAR-T therapy between January 2021 and December 2022, confirms that management with Romiplostim is efficient and feasible.

Keywords:

#

Cite the Article:

Musso M, Tona G, Scalone R, Crescimanno A, Porretto F, Lanza M, et al. Single Center Experience on Management of CAR-T Related Thrombocytopenia. Clin Case Rep Int. 2023; 7: 1476.